Comparative analysis of transcriptomic and proteomic expression between two non-small cell lung cancer subtypes
Ben NicholasiD, Alistair BaileyiD, Katy J. McCanniD, Peter JohnsoniD, Tim J ElliottiD, Christian H. H. OttensmeieriD, Paul J. S. SkippiD
Abstract
Non-small cell lung cancer (NSCLC) is frequently diagnosed at an advanced stage and has poor survival. NSCLC subtypes require different treatment regimes, hence there are extensive efforts to find more precise and non-invasive differential diagnostics tools. Complementing these efforts, we examined two NSCLC subtypes for differences that may inform treatment options and identify potential novel therapeutic pathways. Here we present a comparative analysis of transcriptomic and proteomic expression in tumours from a cohort of 22 NSCLC patients: 8 squamous cell carcinoma (LUSC), 14 adenocarcinoma (LUAD). We examined differential gene and differential protein expression between LUSC and LUAD, and between NSCLC subtypes and either PBMCs or normal adjacent lung tissue (NAT). We found that both NSCLC subtypes shared common differences in gene expression to PBMC relating to developmental and structural changes, and common protein expression differences to NAT relating to protein translation and RNA related processing and splicing. Between NSCLC subtypes we found differential gene expression relating to cell differentiation for LUSC and cellular structure and immune response regulation for LUAD. Differential protein expression between NSCLC subtypes related to extracellular structure for LUSC and metabolic processes, including glucose metabolism for LUAD. Many of our observations of differentially expressed genes and proteins between NSCLC subtypes support and inform existing observations, aiding both basic and clinical research seeking to identify subtype biomarkers or druggable targets.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 5
- FWCI
- 2.04
- Field percentile
- top 14%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- SERPINB13 is a prognostic biomarker for LUSC associated with an immune-inflamed tumor phenotype and modulated by immune cells
Christiane Kuempers, Karina Stein, … Torsten Goldmann·bioRxiv·Jul 16, 2026
- A prognostic signature for lung adenocarcinoma in people who have never smoked
Wei Zhao, Tongwu Zhang, … Maria Teresa Landi·bioRxiv·Aug 13, 2025
- Integrated Multi-Omics Analysis for Molecular Subtyping in NSCLC: A Cohort Study
Bin Yan, Zhangyu Wang, … Shixiang Wang·bioRxiv·Sep 5, 2025
- Comprehensive profiling of genomic and transcriptomic differences between risk groups of lung adenocarcinoma and lung squamous cell carcinoma
Talip Zengin, Tuğba Önal-Süzek·Journal of Personalized MedicinePeer-reviewed·Feb 23, 2021
- Classifying Non-Small Cell Lung Cancer Histopathology Types and Transcriptomic Subtypes using Convolutional Neural Networks
K.-H. Yu, F. Wang, … I. S. Kohane·bioRxiv·Jan 25, 2019
- Identification of Biomarker Genes Based on Multi-Omics Analysis in Non-Small Cell Lung Cancer
Ji Xia, Hai-bin He, … Mingyue Ma·bioRxiv·Sep 5, 2022